Data mining of NCI's anticancer screening database reveals mitochondrial complex I inhibitors cytotoxic to leukemia

Constance J Glover1, Alfred A Rabow, Yasemin G Isgor

  • 1Developmental Therapeutics Program, National Cancer Institute at Frederick, Frederick, MD 21702, USA. cglover@mail.ncifcrf.gov

Biochemical Pharmacology
|November 18, 2006
PubMed

Insights

Researchers identified novel mitochondrial complex I inhibitors with anticancer potential. These compounds show significant cytotoxicity against leukemia cells, particularly K562, reinforcing mitochondria as a key cancer target.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Mitochondria play a crucial role in apoptosis, making them attractive targets for cancer chemotherapy.
  • Inhibitors of mitochondrial complex I (NADH:CoQ oxidoreductase) have demonstrated antitumor activity and the ability to induce apoptosis.

Purpose of the Study:

  • To identify novel mitochondrial complex I inhibitors with anticancer activity.
  • To utilize National Cancer Institute (NCI) data mining strategies to find potential chemotherapeutic agents.

Main Methods:

  • Analysis of self-organized maps (SOM) data from the NCI's Developmental Therapeutics Program (DTP).
  • Screening of 10 compounds with unknown mechanisms for complex I inhibition using bovine heart sub-mitochondrial particles (SMP).
  • Cytotoxicity assessment of identified inhibitors against NCI tumor cell lines, focusing on leukemia subpanels.

Main Results:

  • Five out of ten tested compounds significantly inhibited mitochondrial complex I activity, with three showing nanomolar IC50 values.
  • The identified inhibitors demonstrated potent cytotoxicity against leukemia cell lines, especially K562.
  • Inhibition of complex I activity in K562 cells correlated with results from bovine heart SMP experiments.

Conclusions:

  • Mitochondrial complex I is a viable molecular target for anticancer drug development.
  • The data mining approach using SOM clusters is effective for identifying promising complex I inhibitors.
  • Further investigation of these compounds is warranted for their potential as novel chemotherapeutic agents.